They are funded through until at least mid next year by which time they will have results of three phase 2 trials. The most important milestone this year is the interim data release for SNT 5505 in myelofibrosis - and a presentation at ASH in December. Spec buy and hold until then in my opinion.
Ann: Phase 2 Trial Reaches 50% Recruitment, page-5
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
-0.001(5.26%) |
Mkt cap ! $21.49M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.8¢ | $51.60K | 2.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1220998 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1144720 | 4 |
View Market Depth
| Last trade - 16.10pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
1.8¢ |
Change
-0.001 ( 5.26 %) |
||||
| Open | High | Low | Volume | ||
| 1.9¢ | 1.9¢ | 1.8¢ | 2253408 | ||
| Last updated 15.56pm 22/05/2024 ? | |||||
| SNT (ASX) Chart |